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An ever growing number of reports on graft rejection and/or failure even with good HLA 
matches have highlighted an important role of non-HLA antigens in influencing allograft 
immunity. The list of non-HLA antigens that have been implicated in graft rejection in 
different types of organ transplantation has already grown long. Of these, the Major 
Histocompatibility Complex class I chain-related molecule A (MICA) is one of the most 
polymorphic and extensively studied non-HLA antigenic targets especially in the kidney 
transplantation. Humoral response to MICA antigens has repeatedly been associated 
with lower graft survival and an increased risk of acute and chronic rejection following 
kidney and liver transplantation with few studies showing conflicting results. Although 
there are clear indications of MICA antibodies being associated with adverse graft out-
come, a definitive consensus on this relationship has not been arrived yet. Furthermore, 
only a few studies have dealt with the impact of MICA donor-specific antibodies as 
compared to those that are not donor specific on graft outcome. In addition to the 
membrane bound form, a soluble isoform of MICA (sMICA), which has the potential to 
engage the natural killer cell-activating receptor NKG2D resulting in endocytosis and 
degradation of receptor–ligand interaction complex leading to suppression of NKG2D-
mediated host innate immunity, has been a subject of intense discussion. Most studies 
on sMICA have been directed toward understanding their influence on tumor growth, 
with limited literature focusing its role in transplant biology. Furthermore, a unique 
dimorphism (methionine to valine) at position 129 in the α2 domain categorizes MICA 
alleles into strong (MICA-129 met) and weak (MICA-129 val) binders of NKG2D receptor 
depending on whether they have methionine or valine at this position. Although the 
implications of MICA 129 dimorphism have been highlighted in hematopoietic stem cell 
transplantation, its role in solid organ transplantation is yet to be explored. This review 
summarizes the currently available information on MICA antibodies, soluble MICA, and 
MICA-129 dimorphism in a setting of solid organ transplantation.
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iNTRODUCTiON
The Major Histocompatibility Complex (MHC) class I-related 
chain genes A and B (MICA and MICB) are a new family of pro-
teins encoded within the human HLA class I genes, first described 
in 1994 by two independent groups of researchers (1, 2). While 
the latter group referred to them as Perth beta block transcript 
11, Bahram and coworkers named them as MIC, a terminol-
ogy that was later adopted by the World Health Organization 
nomenclature committee for factors of the HLA system. Unlike 
the classical HLA molecules, these proteins are not involved in 
antigen presentation to T cells. Instead they act as ligands for 
the activating C-type lectin-like receptor, referred to as natural 
killer (NK) group 2, member D (NKG2D) which is expressed on 
NK cells, γδ T cells, and CD8+ αβ T cells. Interaction of MICA 
with NKG2D leads to activation of antigen-specific cytotoxic 
T-lymphocyte-mediated cytotoxicity, NK cell responses, and 
cytokine production (3). Besides, polymorphic MICA antigens 
are capable of inducing antibodies that may kill target cells in the 
presence of complement (4). Hence MICA is unique to the extent 
that it plays a key role in linking the innate and adaptive immune 
responses in organ transplantation.
GeNeTiC ASPeCTS AND BiOCHeMiCAL 
STRUCTURe
MIC genes are located within the MHC class I region of chro-
mosome 6 p21.3. A total of seven genes, designated as MICA to 
MICG, have so far been described, of which MICA and MICB are 
the only functional genes, while MICC to MICG are essentially 
pseudogenes (5, 6). MICA gene is located centromeric to HLA-B 
locus at a distance of 46.4  kb, and this close proximity results 
in a very strong linkage disequilibrium effect between the two 
(Figure 1).
The domain structure of MICA is much like that of the clas-
sical HLA class I molecules with 30% sequence homology and 
three extracellular domains. Of these, the α1 domain is encoded 
by exon 2, α2 by exon 3, and α3 by exon 4. The transmembrane 
(TM) region is encoded by exon 5, while the carboxy-terminal 
cytoplasmic tail is encoded by exon 6. There are five introns of 
which the first is the largest intron (7). The gene spans 11.7 kb 
region and is transcribed into an mRNA of 1,382 bp, which gives 
rise to 383-amino acid polypeptides of 43  kDa including the 
leader peptide.
Unlike the HLA class I molecules, the MICA does not bind β2-
microglobulin (β2-m) (Figure 2). Though the structure of MICA 
looks very similar to its classical class I counterpart, its α-2 helix 
which is one of the groove defining helices, is disordered and 
flexible making it unsuitable for peptide binding. Furthermore, 
as opposed to the HLA class I molecules, the platform formed 
by the α1 and α2 regions of the MICA molecule points down-
wards toward the cell membrane thus exposing its underside 
to the intercellular space. However, when MICA interacts with 
its receptor NKG2D, the flexible α2 helix becomes ordered by 
a further two alpha-helical turn and the α1 and α2 domains flip 
back 96° (8).
eXPReSSiON PROFiLe OF MiC PROTeiNS
Unlike the ubiquitous expression of classical HLA class I 
molecules, MIC proteins have limited tissue distribution being 
expressed constitutively on epithelial cells especially in the gas-
trointestinal tract (9), endothelial cells, fibroblasts, monocytes, 
keratinocytes (10), and dendritic cells (11). Zwirner and col-
leagues demonstrated that MIC molecules are not expressed on 
resting T or B lymphocytes, and unlike the HLA class I antigens, 
are not upregulated by INF-γ. Nevertheless, the expression of 
MICA can be induced on activated CD4+ T cells through release 
of IL-2 that powerfully induces MICA through calcineurin and 
other pathways in cooperation with CD3 engagement. Using con-
focal microscopy, these investigators found low levels of MICA 
expression on the surface of activated CD4 T cells and stated that 
this might indicate a protective mechanism of T-cell-dependent 
NK cell attack (12). MICA through engagement of NK cells helps 
to accomplish the removal of activated T-cells once the final phase 
of immune response is completed.
In a study involving total body tissue scan of both MICA 
and MICB transcription using Northern blot assay, Schrambach 
et al. reported that both the genes are transcribed in virtually all 
body tissues except the central nervous system (13). The surface 
expression of MICA is enhanced under stress conditions such 
as autoimmune diseases (14), DNA damage (15), ischemia-
reperfusion injury (16), viral infections (17), and inflammation 
(18). Since MICA antigens are also frequently found on tumor 
cells (19), it implies that they are cell stress markers and their 
tissular expression is a signal for destruction by NK cells.
MiCA POLYMORPHiSM
MICA is the most polymorphic non-classical class I gene known 
so far with 105 alleles having already been reported and new 
alleles being continuously identified.1 This polymorphism differs 
from that of the HLA genes in various aspects. First, the mag-
nitude of polymorphism is far less than that seen in the HLA 
system. Second, in contrast to the HLA class I molecules, where 
the polymorphism is located predominently in the proximity of 
antigen binding groove, the MICA polymorphism is dispersed to 
all the three extracellular domains with the greatest variability in 
the α2 domain, encoded by exon 3. Another interesting aspect of 
the polymorphism of MICA is the observed variations in the TM 
region for several MICA alleles despite having identical extracel-
lular domains. Therefore, it is essential to study polymorphism 
in the TM region to avoid typing ambiguities (20). Moreover, 
unlike the polymorphic positions of HLA that typically consists 
of several amino acids, MICA polymorphism is generated mainly 
by single amino acid substitutions (except positions 90 and 91) 
resulting in dimorphism (except residues 156 and 251).
In contrast to MICA, the genetic polymorphism of MICB 
is limited with a total of 45 alleles reported so far.2 There is no 
concrete evidence to indicate its relevance in transplant outcome.
1 http://hla.alleles.org/nomenclature/stats.html, April 14, 2016.
2 http://hla.alleles.org/nomenclature/stats.html, April 14, 2016.
FiGURe 1 | Location of the MiCA gene on the short arm of chromosome 6, centromeric to HLA-B locus. Currently 105 sequenced alleles and 82 protein 
variants of the gene are known.
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MiCA-129 DiMORPHiSM
Despite the highly polymorphic nature of MICA genes, only 
one functional site has been identified that appears to affect the 
binding of MICA ligands to its receptor NKG2D. Accordingly, a 
non-synonymous Methionine to Valine change at position 129 of 
the α2 domain categorizes MICA alleles into “MICA-129 met,” 
which is a strong binder of NKG2D receptor and “MICA-129 
val” having weak binding ability. This dimorphism is identified 
on a single SNP rs1051792 A>G polymorphism at position 454 
in exon 3 of MICA gene, corresponding to amino acid position 
129 of the MICA protein. It has been shown that MICA-129 met 
has a 10- to 50-fold greater capacity to complex NKG2D than 
those with MICA-129 val (21). The functional consequence of 
this dimorphism has recently been studied in great details by the 
group led by Ralf Dressel in Germany (22) who demonstrated that 
MICA-129 met isoforms are able to induce stronger and faster 
NKG2D signaling leading to higher degree of NK cell-mediated 
cytotoxicity and release of INF-γ. This variant was also found to 
mediate faster co-stimulation and activation of CD8+ T cells. 
However, such effects were not sustained because the MICA-129 
variant was able to induce rapid downregulation of the NKG2D 
receptor (22). Furthermore, the same group of investigators 
showed that MICA-129 met isoform is less efficiently expressed 
on the cell surface as compared to the MICA-129 val variant. This 
could be due to the intracellular retention of the former and its 
increased shedding from the cell surface (23). Similarly, like their 
NKG2D receptor counterparts that according to the polymor-
phism in the NKC region can be categorized into high NK cell 
cytotoxicity and low overall cytotoxicity, MICA-129 variants can 
also associate differently in pathological conditions requiring NK 
cell-mediated cytotoxicity.
Several studies have shown an association of met/val dimor-
phism with various diseases which include inflammatory bowel 
disease (24), nasopharyngeal cancer (25), and latent autoimmune 
diabetes (26). Table  1 summarizes all such studies in various 
pathological conditions involving different ethnic groups as per 
literature reports. Although only a limited literature is available 
on the role of met/val dimorphism in transplantation settings, 
a study by Boukouaci et  al. (27) reported a strong association 
of MICA val/val genotype with increased risk of chronic graft-
versus-host disease development in patients undergoing 
hematopoietic stem cell transplantation (HSCT). Furthermore, 
the same study revealed that the serum levels of soluble MICA 
isoform and the presence of antibodies to MICA were associated 
with cGvHD, which is a major complication following HSCT 
(27). Recently, Isernhagen et al., in a cohort of 452 patients who 
underwent HSCT, showed that MICA-129 met tends to increase 
the risk of acute GVHD (aGVHD). Presence of even one MICA-
129 met  allele reduced the probability of developing severe or 
fatal aGVHD (22). The increased risk of aGVHD was explained 
on the fact that the MICA-129 met variant leads to faster and 
more robust NKG2D signaling while the rapid downregulation of 
NKG2D on alloreactive CD8+ T cells explains the reduced severity 
of aGVHD. This effect was even more evident in patients carrying 
homozygous MICA-129 met alleles receiving ATG. In addition, a 
higher relapse rate was observed in patients with MICA-129 met 
as compared to those with MICA-129 val/val genotype because 
TABLe 1 | Summary of MiCA-129 dimorphism studies reported to be associated with various disease conditions in different ethnic groups.
MiCA-129 dimorphism Year No. of patients ethnicity Disease Association Reference
Met/met 2005 129 Algerian Juvenile ankylosing spondylitis Positive Amroun et al. (28)
Val/val 2009 130 Tunisian Nasopharyngeal carcinoma Positive Douik et al. (25)
Val/val 2009 211 French Chronic GVHD Positive Boukouaci et al. (27)
Met/met 2010 88 Spanish Ulcerative colitis Positive Lopez-HernÂndez et al. (24)
Val/val 2011 272 Chinese Ulcerative colitis Positive Zhao et al. (29)
Met/met 2011 716 Japanese Systemic lupus erythematosus Positive Yoshida et al. (30)
Val/val 2012 73 Algerian Type1 diabetes Positive Raache et al. (26)
Met/met 2013 340 Canadian Cutaneous Psoriasis Positive Pollock et al. (31)
Met/met 2013 552 Vietanamese Hepatocellular carcinoma Positive Tong et al. (32)
Met/met 2015 189 Brazil Severity of chronic chagas disease Positive Ayo et al. (33)
Met/met 2015 452 Germany Acute GVHD Positive Isernhagen et al. (22)
FiGURe 2 | Structural similarities between Major Histocompatibility Complex (MHC) class i and ii molecules with MiCA. The latter is equivalent to the 
heavy chain of MHC class I molecule without the β2 microglobulin. While the MHC I and II present peptides to CD8 and CD4 cells, respectively, the MICA recognizes 
NKG2D receptors on the surface of natural killer (NK) cells.
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of reduced graft versus leukemia effect of NK and CD8+ cells 
consequent to downregulation of NKG2D by MICA-129 met 
variants. As a corollary to this, it is reasonable to hypothesize 
that the inflammatory processes-related abovementioned MICA 
features might also influence complications that occur during 
renal allograft rejection. Although immunologically MICA-129 
dimorphism has the potential to affect graft outcome following 
solid organ transplantation, unlike HSCT, there is no published 
literature highlighting its role for the same. This certainly opens 
up a new area of research in renal allograft outcome.
iMMUNe ReSPONSe TO MiCA
The first indication that MICA could act as a new polymorphic 
alloantigen was provided by Zwirner et  al. (34) who reported 
the presence of anti MICA antibodies in the sera of solid organ 
transplant recipients. Later, similar antibodies were reported 
in mice immunized with recombinant MICA (4). These inves-
tigators also demonstrated MICA as a target for complement-
dependent cytotoxicity. Few years later, the landmark study by 
Zhang and Stastny (35) demonstrated that immunization of mice 
with recombinant MICA*001 having all the three extracellular 
domains, could elicit responses in both T and B cells. While the 
former showed the predominance of CD4+ T-cells, proliferating 
CD8+ T cells were also present and the stimulated CD8+ T cells 
were able to kill target cells pulsed with MICA by cell-mediated 
cytotoxicity. Furthermore, MICA stimulated CD4+ T cells were 
Th2 skewed, secreting high levels of IL-4 and correspondingly 
low levels of INF-γ. Thus these cells seem to provide a powerful 
aid to responding B cells.
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Although MHC class II or class I antibodies are able to inhibit 
the proliferation of CD4+ and CD8+ T cells, respectively, the 
same is not the case with blocking of the NKG2D receptor. This 
led to the conclusion that T-cell response induced by MICA is 
confined to classical MHC molecules, which is in accordance 
with the indirect allorecognition of MICA peptides presented 
by host MHC antigens. In order to explain an efficient immune 
response elicited by MICA antigens despite the restricted poly-
morphism and much less amount of MICA on the cell surface 
as compared to HLA, Stastny and his group (36) proposed that 
“in addition to the adaptive immune response of T and B cells 
against an alloantigen, MICA also is capable of setting in motion 
the mechanisms of innate immunity. Co-stimulation by engage-
ment of NK cells might have the effect of potentiating the T and B 
cell response. Another possibility might be that MICA is in itself 
rather immunogenic and capable of eliciting a response from a 
large repertoire of cells through any of a variety of mechanisms. 
This could result from cross-reactivity with unidentified microor-
ganisms, expansion of the repertoire of responding immune cells, 
other genetic factors that might determine the magnitude of the 
specific immune response, or perhaps structural features of the 
MICA molecules that make them immunogenic.” Taken together, 
these findings support the concept that MICA antigens play a role 
in human allograft rejection by activating both humoral as well 
as cellular mechanisms. Furthermore, upregulation of NKG2D by 
interleukins, NK cell activation (in case of inflammatory condi-
tions), NK cell-induced dendritic cell maturation, and subsequent 
activation of alloreactive T cells as well as NKG2D-mediated 
decrease in regulatory T cells could contribute to graft rejection 
and graft loss in transplantation (3). It may be mentioned that 
cellular stress-induced expression of MICA such as on renal 
tubules could either augment NKG2D-mediated co-stimulation 
of cytotoxic T cells or direct activation of alloreactive CD8+ T 
cells through TCR independent mechanism (3, 37). At the same 
time, an ever increasing amount of data has highlighted a possible 
association between anti-MICA antibodies and graft rejection 
(38). The possible mechanisms for MIC-mediated allograft rejec-
tion include development of anti-MICA antibodies, recognition 
of MIC on allografts, and NKG2D-mediated cytotoxicity.
MiCA ANTiBODieS: ReLevANCe iN SOLiD 
ORGAN TRANSPLANTATiON
Following the first demonstration of the expression of MICA 
antigens on endothelial cells (10), attention was directed toward 
investigating the possibility of these molecules being a target for 
graft destruction in solid organ transplantation. Soon, the same 
group of investigators showed that antibodies in patient’s serum 
could specifically react with different recombinant MICA mol-
ecules (34). Others also demonstrated the expression of MICA 
on renal and pancreatic allograft biopsies (39) and confirmed it 
to be a target for complement-dependent cytotoxicity using both 
mouse MICA monoclonal antibodies as well as human alloanti-
bodies (4). Similarly, in a study on 139 renal allograft recipients, 
Sumitran-Holgersson et al. (40) showed a significant correlation 
of MICA antibodies with graft loss. Thus, the year 2002 was an 
important milestone in providing evidence that MICA expres-
sion in graft tissues could lead to antibody-mediated lysis and that 
MICA antibodies could have an important role in precipitating 
antibody-mediated rejection (AMR). This was followed by a lull 
period of 3 years before Mizutani and coworkers (41) published 
a retrospective study of “serial ten-year follow up of HLA and 
MICA antibody production prior to kidney graft failure” provid-
ing evidence that patients who had both antibodies rejected their 
grafts more frequently than those who did not have either of these 
antibodies. Another study by the same authors indicated that 
MICA antibodies detected at pretransplant period could have 
a role in the development of AMR (42). The above mentioned 
studies along with the development of more reliable and conveni-
ent Luminex bead based assay system opened the floodgates for 
several studies investigating the relevance and impact of MICA 
antibodies on allograft outcome. Hence, the year 2007 witnessed 
a surge in studies investigating the effect of MICA antibodies on 
graft outcome in solid organ transplants, more so in kidney and 
heart transplants. Table  2 summarizes relevant studies on the 
influence of MICA antibodies on graft outcome in various solid 
organ transplantations.
ReNAL TRANSPLANTATiON
impact of Pretransplant MiCA Antibodies
Exact mechanisms by which individuals develop antibodies to 
MICA are largely unknown. Although, pregnancy per  se and 
previous transplants can sensitize the patient leading to the 
development of anti-MICA antibodies (34), the role of blood 
transfusions in their induction is not fully clear (43, 44).
The first major study to evaluate the potential association of 
MICA antibodies with overall allograft survival was conducted by 
Zou et al. (43). It was an international collaborative study involv-
ing 20 centers in 13 countries with pre transplant serum samples 
obtained from 1,910 patients. The experiment was performed 
blindly by testing MICA antibodies without any knowledge of 
the clinical course. The results showed that at least 217 of the 
1,910 patients (11.4%) had MICA antibodies and their 1-year 
graft survival (GS) was 88.3% as compared to 93% in the group 
without MICA antibodies (p = 0.01). Among patients of primary 
renal grafts, survival was even lower (87.8%) compared with 
93.5% for those who did not have MICA antibodies (p = 0.005). 
Interestingly the association of MICA sensitization with GS was 
observed in patients well matched for HLA. Independent analysis 
of 326 patients with 0 or 1 HLA-A, -B, or DR mismatches also 
showed that recipients with MICA antibodies had poorer GS of 
83.2% compared to 95.1% of those without MICA antibodies. 
However, the study did not investigate the impact of possible 
confounding factors that are likely to influence graft loss.
Subsequently, Lemy and colleagues (44) studied for the pres-
ence of MICA antibody in sera from 494 healthy controls and 597 
patients with chronic kidney disease (CKD) stage V and reported 
threefold higher prevalence of MICA antibodies in patients with 
CKD when compared with controls. Using logistic regression 
analysis involving subsets of patients free of transfusions and 
transplantation also revealed at least twofold higher prevalence 
TABLe 2 | Presence of MiCA antibodies and their effect on allograft outcome in solid organ transplantation.
Organ Detection time Year Number of 
patients
Transplant (DD/LD) Follow-up (duration) Reference Outcome
Kidney Pre-tx 2002 139 DD 3 months Sumitran-Holgersson et al. (40) ↑AMR
2007 1,910 DD 1 year Zou et al. (43) ↑AMR, ↓GS
2010 425 NS 1, 5, and 10 years Lemy et al. (44) ↔
2012 40 LD 1 year Solgi et al. (45) ↔
2013 727 DD + LD 3, 6, 12, and 24 months Sánchez-Zapardiel et al. (46) ↑AMR
Post-tx 2005 145 DD + LD 10 years Mizutani et al. (41) ↓GS
2007 185 LD Panigrahi et al. (47) ↑AMR
2007 1,921 DD + LD 4 years Terasaki et al. (48) ↓GS
2009 284 DD 3 years Suarez-Alvarez et al. (49) ↑AMR
2011 442 DD + LD 5.9 years (mean) Cox et al. (50) ↑CR
2012 779 DD + LD 4 years Lemy et al. (51) ↔
2012 147 DD + LD 6 months Seyhun et al. (52) ↔
Heart Pre and post-tx 2007 44 DD 1 year Suarez-Alvarez et al. (53) ↑AMR
Pre-tx 2009 491 DD 1 and 5 years Smith et al. (54) ↔AMR/CAV ↑GS
Pre-tx 2010 63 DD 6 months Pavlova et al. (55) ↔
Post-tx 2010 95 DD 1.8 and 8.9 years (mean) Nath et al. (56) ↑AMR, ↑CAV
Post-tx 2011 168 DD 2 years (median) Zhang et al. (57) ↑AMR
2015 05 Animal experiments 
(rat-to-mouse cardiac 
transplantation model)
Yu et al. (58) ↑AR
Liver 2008 84 NS 2 years Uzunel et al. (59) ↔
2013 123 NS 7 years Ciszek et al. (60) ↔
MICA, major histocompatibility complex class I chain-related molecule A; AT1R, angiotensin II type 1 receptor; AECA, anti-endothelial cell antibody; Col V, collagen V; KA1T, k-α1 
tubulin; LSECs, liver sinusoidal endothelial cells; AMR, antibody-mediated rejection; GS, graft survival; AVR, acute vascular rejection; CAV, cardiac allograft vasculopathy; BOS, 
bronchiolitis obliterans syndrome; DD, deceased donor; LD, live donor; NS, not specified; AR, acute rejection; ↔, no adverse effect.
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of MICA antibodies in CKD patients when compared to healthy 
controls. It is intriguing that these antibodies were more frequent 
in males rather than females in the cohort as a whole (14 versus 
7%) and also among individual groups despite pregnancy being 
an independent risk factor for their development. Thus factors 
remaining significantly associated with MICA antibodies after 
logistic regression analysis were blood transfusions, previous 
transplantation, and females with two or more pregnancies. The 
finding of blood transfusion as a significant sensitizing event was 
in sharp contrast with the findings of Zou although five transfu-
sions were required for categorization as “transfused” compared 
to only one in Zou’s study (43). Another very interesting finding 
of this study was that no sensitizing events could be identified in 
a third of the patients with MICA antibodies and CKD stage V, 
implicating other possible mechanisms for MICA sensitization. 
Additionally, 20% of CKD patients had MICA antibodies that 
were auto-reactive, a rare finding with HLA antibodies (61).
It is important here to debate on the results of two important 
studies—one carried out by Zou et  al. (43) and the other by 
Lemy and colleagues (44). Even though the broad design of 
the two studies has been similar with pretransplant testing for 
MICA antibodies, the outcomes were dissimilar in terms of GS. 
Furthermore, there were differences in the number of patients 
included in the two studies, but the latter group of investigators 
found better survival in patients positive for MICA antibodies, 
albeit insignificantly. However, an analysis of immunosuppres-
sion protocols between the two studies showed that Lemy’s 
group of patients were more heavily immunosuppressed and 
that could make an effect on the incidence and impact of MICA 
antibodies. Others also failed to show significantly higher 
rejection rates in patients expressing MICA antibodies as com-
pared to those who did not express (62). Similarly, Solgi et al. 
(45) did not find significant difference in rejection episodes on 
comparing patients with or without the presence of anti-MICA 
antibodies. A retrospective study involving 727 renal allograft 
recipients published by Sánchez-Zapardiel et  al. (46) revealed 
a 7.15% prevalence of MICA antibodies in patients waiting for 
a renal transplant. They reported that preformed anti-MICA 
antibodies significantly increased the risk for allograft rejection 
particularly early after transplantation and that this effect was 
independent of the presence of anti-HLA antibodies. However, 
no significant difference was noticed in allograft survival and 
rejection rates at 2-year follow-up. Moreover, no significant 
epidemiological or clinical differences were observed between 
MICA antibody positive and negative groups. The study did 
not define the donor specificity of anti-MICA antibodies. The 
same group of authors further demonstrated that presence of 
anti-MICA antibodies at pretransplant periods can bind native 
MICA molecules on the cell membrane and was able to mediate 
cell death by fixing and activating the complement cascade by 
using both the C1q single-antigen beads assay and complement-
dependent cytotoxicity (63).
Our experience with live donor renal transplantation (64) is 
very similar to that of others (65, 66) suggesting that presence 
of pretransplant MICA antibodies especially those against donor 
antigens with MFI in the range of 10,000–20,000 are capable of 
causing hyperacute and acute rejection (AR). Clearly, there are 
gap areas and lack of consensus on the epidemiology and specific-
ity of MICA antibodies on the one hand and their impact on AR 
and GS on the other.
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impact of Posttransplant MiCA Antibodies
The issue of de novo occurrence of MICA antibodies posttrans-
plantation has been a subject of intense investigation. In a study 
involving 185 consecutive live related donor renal transplant 
patients, we analyzed posttransplant serum samples at varying 
time periods and reported a significant decline in 2-year GS if 
both HLA and MICA antibodies were detected (47). The survival 
was only 17% compared to 89% of those with no antibodies. 
Furthermore, patients with either MICA or HLA antibodies 
alone also had a significantly reduced GS of 71% as compared to 
the no antibody group.
Simultaneously, a large collaborative international study 
coordinated by Paul Terasaki tested sera for both HLA and MICA 
antibody production from 1,329 recipients of renal grafts (964 
from deceased donors and 365 living donors) from 21 participat-
ing centers as a part of the 13th International Histocompatibility 
and Immunogenetics Workshop Conference (IHIWC) and 22 
centers as a part of the 14th IHIWC (48). Only those recipients 
who did not produce HLA antibodies pretransplant (pretrans-
plant testing for MICA antibodies was not performed) and who 
survived for more than 6 months were included in this study. 
HLA antibodies were detected with CDC, ELISA, or Luminex 
techniques, while MICA antibodies were detected using eight 
different recombinant MICA molecules produced in HMY2.
C1R cells, isolated and coated on Luminex beads. In the 13th 
workshop, the 4-year deceased donor GS among 806 patients 
who were negative for HLA antibodies was 81% as compared 
to 58% for 158 recipients with HLA antibodies (p <  0.0001) 
and 72% for 69 patients with the presence of MICA antibod-
ies (p =  0.02). Among those with living donor grafts, 4-year 
GS was 78% for 275 patients without HLA antibodies, 62% for 
90 patients with HLA antibodies (p = 0.0008), and 80% for 21 
patients with MICA antibodies (p = NS). In the 14th workshop, 
1-year GS for deceased donor recipients without MICA antibod-
ies was 96.8% as compared to 82.7% for 33 patients with MICA 
antibodies alone (p  =  0.0005). However, the same was not 
observed with living donor recipients as 19 patients with MICA 
antibodies had 100% 1-year GS. Multivariate analysis at both 
time points revealed that MICA antibodies were significantly 
and independently associated with reduced GS in deceased 
donor grafts, providing strong evidence for the involvement of 
these antibodies with graft rejection. It may be mentioned that 
these studies did not consider previous AR episodes or other 
confounding factors that are also likely to influence graft loss. 
The explanation for the lack of significance of MICA antibodies 
in living donor transplants was attributed to the limited number 
of patients in the study group.
Up until around 2009, the specificity of MICA antibodies and 
epitopes recognized by them had received very little attention. 
Gautier et al. (67) performed MICA typing of 43 recipient–donor 
pairs of patients undergoing third renal transplant and also evalu-
ated MICA antibody using the LABScreen SAB Luminex method 
(One Lambda). The antibody screening was done on the day of 
transplant and after 1 year. They observed greater frequency of 
patients with two MICA mismatches among those who devel-
oped rejection; whereas all patients with graft losses had 0 or 1 
MICA mismatch. Antibodies specific to donor MICA antigens 
(MICA-DSA) were found to be equally associated with functional 
and failed grafts. In this study, although MICA genotyping was 
attempted on all patients and donors including those positive for 
MICA antibodies, the authors did not examine the nature of mis-
matches between those who produced de novo MICA antibodies 
and those that did not.
At around the same time, Suarez-Alvarez and colleagues 
(49) combined a clinical study of MICA antibody production in 
deceased donor renal transplantation along with MICA epitope 
analysis. Posttransplant sera of 284 patients were tested for MICA 
antibodies using Luminex technology, and patients were followed 
for up to 3 years. The results revealed presence of MICA antibodies 
alone without the presence of anti-HLA antibodies in 30 (10.6%) 
patients. Furthermore, 29.6% of patients who developed AR had 
MICA antibodies as compared to 13.3% of the antibody nega-
tive group (p < 0.05). Using epitope mapping with a synthesized 
library of overlapping peptides from the extracellular domains 
of MICA molecules, the investigators determined nine antigenic 
regions reactive with MICA antibodies in patient’s serum. Four of 
these regions were mapped to variable sites in the molecule with 
polymorphic amino acids while five antigenic regions located in 
constant region had shared epitopes found in all MICA alleles.
Others used a novel technique to detect de novo HLA and 
MICA antibodies in 15 patients following renal transplanta-
tion (68). Pre- and posttransplant sera were profiled using the 
Invitrogen Protoarray Human Protein Microarray platform 
containing 5,056 non-redundant human proteins, purified from 
insect cells. For the purpose of analysis, three main clinical 
phenotypes with five patients each were considered (i) the first 
group comprised of patients positive for C4d and undergoing 
AR, (ii) the second group with cellular rejection were negative 
for both donor-specific antibodies (DSA) and C4d, and (iii) 
the third group consisted of patients with stable graft function 
without any rejection episodes. The results revealed de novo 
occurrence of MICA antibodies in 11 of the 15 patients with the 
mean antibody signal intensity being higher in those with C4d+ 
AR as compared to those with C4d− AR. Additionally, integrative 
genomics predicted localization of MICA antigen to the glomeru-
lus in the normal kidney. Immunohistochemistry confirmed the 
finding that MICA antigens preferentially localized to glomerular 
podocytes. MICA expression in normal kidney podocytes may 
actually be a means to resist NK cell-mediated cytotoxicity. These 
investigators also showed the induced expression of MICA in vivo 
on infiltrating lymphocytes during rejection episodes suggesting 
that MICA antibody-mediated immune responses occurred 
irrespective of graft rejection and that antibody levels increase 
during AMR but not cellular rejection. Therefore, keeping in view 
the significant rise in antibody titers prior to and during humoral 
rejection, serial measurement of MICA antibody levels rather 
than checking cross-sectionally at the time of rejection may be 
more useful. Besides the observed correlation between C4d+ AR 
and high MICA levels, the latter were also significantly associated 
with MHC class II-specific circulating DSA. Since an association 
of HLA-DSA class II with development of chronic glomerular 
injury is already established, it is possible that anti-MICA anti-
bodies may be playing a potentiating role in the pathogenesis of 
chronic transplant glomerulopathy.
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Whether there is an influence of MICA allele mismatching on 
antibody production and graft rejection is not fully clear? Cox 
and coworkers (50) screened 442 renal transplant recipients for 
MICA antibodies using three different Luminex-based single 
antigen kits—One Lambda, Gen-Probe, and an “in-house” assay. 
Mean time for testing of antibodies was 7  months after trans-
plantation and the mean follow-up period was 5.9 years. MICA 
antibody specificities were considered positive only if confirmed 
by at least two different kits. In 227 of the above recipient-donor 
pairs, MICA allele typing was performed by DNA sequencing. At 
least 17 recipients (7.5%) developed MICA antibodies of which 
10 had de novo DSA. Moreover, eight of these MICA+ recipients 
and seven of those who had de novo DSA had no HLA antibodies. 
On multivariate analysis, MICA mismatching was found to be an 
independent significant factor associated with the development of 
MICA antibodies. Also the presence of both MICA and HLA anti-
bodies together significantly correlated with ACR but not AMR, 
although occurrence of MICA antibodies alone failed to show an 
association with either of these events. Nevertheless, recipients 
with MICA DSA alone showed a significant association with graft 
dysfunction (↓ eGFR) 2 years following transplantation, as were 
those with HLA-DSA alone who showed significantly reduced 
eGFR after 3  years. Thus the kinetics of antibody response in 
this study pointed toward an accelerated graft dysfunction in the 
presence of MICA antibodies.
In a retrospective study performed by Lemy et  al. (51) on 
1-year posttransplant sera from 779 renal transplant recipients, 
a 5.4% prevalence of MICA antibodies was observed. MICA+ 
patients were more frequently HLA sensitized and had to undergo 
re-engraftment. There was no significant difference in 4-year 
death-censored GS between MICA positive and negative patients 
(97 versus 94%, p = 0.28). By Cox multivariate analysis, graft loss 
was found to be independently associated with the number of 
HLA-DR mismatches, AR within the first year posttransplanta-
tion, 1-year serum creatinine ≥1.5  mg/dl, and the presence of 
HLA antibodies at 1 year, but not the presence of MICA antibod-
ies. Another study comprising of 84 renal allograft recipients 
with a follow-up of 4 years reported that more than one-third of 
the recipients developed antibodies to HLA and/or MICA and 
the percentage of recipients who developed de novo antibodies 
increased with time after transplantation elapsed. Recipients 
positive for these antibodies had higher serum creatinine levels 
and worse allograft function than those without antibodies (69).
HeART TRANSPLANTATiON
A number of studies have shed light on the correlation of MICA 
antibodies to cardiac allograft rejection episodes. Suarez-Alvarez 
(70) demonstrated significant correlation between the presence 
of anti-MICA antibodies detected by CDC using recombinant 
cell lines and AR following heart transplantation. A year later, 
the same group performed another study to investigate a pos-
sible relationship between MICA antibody production and 
heart allograft rejection in 44 recipients (53). This time, MICA 
antibodies were detected using both MICA transfected cell lines 
in a CDC assay and a commercial assay using Luminex beads. 
While a quarter of the patients were antibody positive by the 
CDC technique, only seven (15.9%) showed MICA antibody by 
the Luminex assay. Nine patients had rejection and a majority 
of them (60%) were positive for MICA antibodies by the CDC 
method as compared to five patients (14.3%) without rejection 
(p = 0.0038). Analysis by Luminex revealed 55.5% of AR patients 
as compared to only 6% without rejection had MICA antibodies 
(p = 0.0020). They also performed MICA allele DNA-typing for 
donors and recipients where the recipient was positive for MICA 
antibodies. All patients with MICA antibodies and AR had 
MICA-DSA although five patients also had autoantibodies. This 
study was limited by the small number of patients; nevertheless it 
was the first study to show a possible correlation between MICA-
DSA and AR. Additionally, they determined MICA mRNA levels 
in endomyocardial biopsies obtained from 10 cardiac transplant 
recipients and found these to be higher in biopsies showing 
rejection than those without it. In majority of the cases, MICA 
expression was higher immediately following transplantation, 
independent of the rejection event, suggesting an upregulated 
antigen expression due possibly to cellular stress.
In contrast to the above, Smith and coworkers (54) in their 
study on 491 heart transplant recipients did not find any sig-
nificant correlation of pre- or posttransplant MICA antibodies 
or MICA-DSA with cardiac allograft survival, AR episodes, or 
cardiac allograft vasculopathy (CAV). Similar observations were 
made by Pavlova et  al. (55) who reported from their study of 
68 heart transplant recipients that patients with pretransplant 
MICA antibodies did not significantly associate with AMR 
or ACR, although a trend was observed with AMR (p = 0.06). 
Others however demonstrated a significant association of anti-
MICA antibodies with AR and CAV (56). These investigators also 
showed that development of HLA-DSA preceded the detection of 
MICA antibodies. An apparent explanation given by the authors 
was that this could be because of binding of HLA-DSA to the 
allograft giving rise to inflammatory cascade, which may result 
in upregulation of MICA antigens, alloreactivity, and sensitiza-
tion. Another study found a significant correlation between the 
presence of MICA-DSA with AMR, while anti-MICA antibodies 
that were not donor specific (NDSA) did not correlate (57). 
In this study, 10% of the patients developed autoantibodies to 
MICA, but these did not associate with the development of AMR. 
Using an allogeneic animal model system involving rat-to-mouse 
cardiac transplants, Yu and coworkers (58) reported high MICA 
expression in recipients’ heart and provided evidence to show that 
anti-MICA antibodies in their sera were associated with high risk 
of AR.
LiveR TRANSPLANTATiON
There are only limited studies defining the role of MICA antibod-
ies in liver transplantation. A study of MICA antibody production 
in liver allograft recipients did not reveal an association with 
allograft rejection (59). Histological analysis revealed that MICA 
is not normally expressed on liver cells and its expression is not 
induced during rejection episodes. Ciszek and coworkers (60) 
analyzed the impact of anti-HLA and anti-MICA antibodies in 
123 ABO compatible liver transplant recipients with a follow-up 
FiGURe 3 | (A) Interaction of NKG2D receptor with its ligand MICA, expressed on endothelial cells, results in activation of NK cells leading to their damage. (B) Over 
expression of MICA on endothelial cells membrane and its proteolytic shedding from the surface leading to the formation of sMICA. The latter interacts with the 
NKG2D receptor, resulting in its internalization and subsequent suppression or impairment of NKG2D-mediated immune response; (C) preformed or de novo-
developed MICA antibodies recognize MICA antigens present on the allograft leading to acute or chronic rejection; (D) potential impact of MICA-129 met/val 
dimorphism on renal graft outcome. Patients expressing met/met in homozygous state are prone to rejection episodes than those with val/val genotype.
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of 7 years. They reported that neither the presence of anti-HLA 
nor anti-MICA antibodies correlated with acute graft rejection 
or GS.
SOLUBLe MiCA (sMiCA): ROLe iN SOLiD 
ORGAN TRANSPLANTATiON
In addition to the membrane bound form, a soluble isoform of 
MICA (sMICA) derived from the proteolytic shedding of mem-
brane bound molecule appears in the serum. MICA, a ligand 
for NKG2D receptors, forms a complex with ERp5, a disulfide 
isomerase/chaperone and induces a conformational change 
enabling proteolytic cleavage of MICA by ADAM proteases. The 
interaction of NKG2D by the sMICA results in the endocytosis 
and degradation of receptor–ligand complex and thus suppresses 
NKG2D-mediated host innate immunity (Figure 3).
Most studies on soluble MICA release in the serum have been 
directed toward understanding their influence on tumor growth, 
with very little literature available on the associated biology. The 
intricate nexus between the science behind sMICA role in cancers 
and transplant rejection has been highlighted through a few 
studies. For example, Suarez-Alvarez et al. (70), while evaluating 
the role of MICA on heart graft acceptance, demonstrated an 
inverse relationship between sMICA levels and AR. The study 
was conducted on 31 heart transplant recipients with a follow-up 
of 1 year, of which 8 patients suffered AR while the remaining 
23 patients did not develop AR. Further analysis showed that 17 
out of 23 patients without AR had detectable levels of sMICA as 
compared to two patients in the rejected group (p < 0.03). On 
combined analysis of MICA antibodies and sMICA, the authors 
found tendency for MICA antibodies to occur in the absence of 
sMICA in the AR group of patients. Conversely, the sMICA levels 
were detected in patients without MICA antibodies and in absence 
of AR. These authors published another paper in the same year, 
where they monitored sMICA levels in pretransplant serum sam-
ples and at 15 days, 3 months and 1 year posttransplantation, in 
34 heart transplant recipients (71). sMICA was practically absent 
in the pretransplant sera, while it was detected in 21 patients at 
15 days posttransplantation. Interestingly, 20 of these 21 patients 
did not develop AR (p = 0.0001), whereas 9 of the 13 patients, 
in whose serum sMICA was not detected, developed AR. These 
observations are in conformity with the previous study suggest-
ing that presence of sMICA contributes to better graft acceptance. 
Recent experiment conducted on an animal model (rat-to-mouse 
cardiac transplantation) also demonstrated a negative association 
of sMICA with AR. The investigators reported that xenografts 
having anti-MICA antibodies and experiencing AR tended to 
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develop in the absence of sMICA (58). Assadiasl and coworkers 
(72) in their study on 30 each patients of coronary artery disease 
and transplant recipients with stable grafts and 15 healthy controls 
did not find any significant difference in the presence and amount 
of soluble MICA between the three groups.
Zou et al. (73), in an attempt to assess the effect of sMICA on 
the outcome of liver transplantation, evaluated levels in pre- and 
posttransplant sera from 133 consecutive primary liver transplant 
patients and in sera from 88 healthy volunteers using sandwich 
ELISA. The study revealed that 37.6% of recipients had signifi-
cantly higher pretransplant sMICA than the healthy population, 
while recipients with decreased posttransplant sMICA following 
liver transplantation had a lower incidence rate of biliary cast 
syndrome (BCS) than those with sustained high levels of sMICA 
after transplantation (10.5 versus 38.7%, p = 0.0302) suggesting 
that dynamic changes in these levels are associated with BCS 
development.
Clearly, there is a general dearth of published literature 
evaluating a possible correlation between circulating levels of 
sMICA and graft outcome in solid organ transplantation. Studies 
involving larger cohorts and diverse ethnic groups are needed to 
determine the applicability of sMICA as a potential biomarker of 
prognostic importance in solid organ transplantation.
CONCLUSiON
Despite clear indications of MICA antibodies impacting graft 
outcome adversely, a definitive consensus on this relationship is 
yet to be arrived. Furthermore, only a few studies have dealt with 
the impact of MICA-DSA as compared to those that are NDSA 
on graft outcome. Two factors are important while analyzing the 
role of MICA antibodies: (i) currently employed pretransplant 
crossmatch procedures are not sensitive enough to detect MICA 
DSA and (ii) the currently used immunosuppressants for induc-
tion and maintenance may not be effective in suppressing the 
immune response against MICA antigens because they are all 
directed at suppression of T cell response albeit through different 
mechanisms. Data so far suggest that circulating levels of soluble 
MICA could well prove to be a potential biomarker of prognostic 
importance in the assessment of patients after renal transplan-
tation. At the present moment, there is scarcity of published 
literature evaluating a possible correlation between production 
of sMICA and their titers with graft outcome in renal transplanta-
tion. Further studies involving larger cohorts and diverse ethnic 
groups could help to reinforce the current findings. Our data on 
MICA-129 dimorphism adds another dimension in defining its 
exact role and influence following solid organ transplantation.
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